Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry.

Abstract:

PURPOSE:The aim of this study was to investigate whether young age at onset of breast cancer is an independent prognostic factor in patients from the Japanese Breast Cancer Registry, after adjustment of known clinicopathological prognostic factors. METHODS:Of the 53,670 patients registered between 2004 and 2006 and surveyed after a 5-year follow-up prognosis, 25,898 breast cancer patients (48.3 %), who were obtained prognostic data, were examined. Clinicopathological factors were compared between young adult (YA; <35 years), middle-aged adult (MA; 35-50 years), and older adult (OA; >50 years) patients. Five-year disease-free survival (DFS) and overall survival (OS) rates were studied. RESULTS:YA patients were associated with an advanced TNM stage and aggressive characteristics (e.g. human epidermal growth factor receptor 2 (HER2)-positive or oestrogen receptor (ER)-negative breast cancers) compared to MA and OA patients (P < 0.001). The 5-year DFS and OS rates were 79.4 % and 90.8, 88.5 and 95.0 %, and 87.8 % and 91.6 % for YA, MA, and OA patients, respectively. From the multivariable regression analysis, young age at onset was confirmed as an independent prognostic factor for both DFS (hazard ratio 1.73, 95 % confidence interval 1.42-2.10; P < 0.001) and OS (hazard ratio 1.58, 95 % confidence interval 1.16-2.15; P = 0.004). CONCLUSIONS:Young age at onset is an independent negative prognostic factor in breast cancer. Further studies are required to develop new therapeutic strategies for YA breast cancer patients.

authors

Kataoka A,Iwamoto T,Tokunaga E,Tomotaki A,Kumamaru H,Miyata H,Niikura N,Kawai M,Anan K,Hayashi N,Masuda S,Tsugawa K,Aogi K,Ishida T,Masuoka H,Iijima K,Kinoshita T,Nakamura S,Tokuda Y

doi

10.1007/s10549-016-3984-8

subject

Has Abstract

pub_date

2016-11-01 00:00:00

pages

163-172

issue

1

eissn

0167-6806

issn

1573-7217

pii

10.1007/s10549-016-3984-8

journal_volume

160

pub_type

杂志文章
  • Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis.

    abstract::Inflammatory breast cancer (IBC) is a rare and aggressive disease. Previous studies have shown that among patients with stage III breast cancer, IBC is associated with a worse prognosis than noninflammatory breast cancer (non-IBC). Whether this difference holds true among patients with stage IV breast cancer has not b...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3436-x

    authors: Fouad TM,Kogawa T,Liu DD,Shen Y,Masuda H,El-Zein R,Woodward WA,Chavez-MacGregor M,Alvarez RH,Arun B,Lucci A,Krishnamurthy S,Babiera G,Buchholz TA,Valero V,Ueno NT

    更新日期:2015-07-01 00:00:00

  • Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis.

    abstract::Triple-negative breast cancer (TNBC) is a subtype of breast tumor with unique characteristics in terms of clinical-pathological presentation, prognosis, and response to therapy. Epidemiological investigations focusing on the identification of risk factors involved in the onset and progression of TNBCs have identified ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s10549-012-2339-3

    authors: Pierobon M,Frankenfeld CL

    更新日期:2013-01-01 00:00:00

  • Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells.

    abstract::Clinical evidence indicates that higher levels of estrogen receptor beta (ERbeta) predicts improved disease-free and overall survival in patients treated with adjuvant tamoxifen therapy. To better understand the mechanisms in which ERbeta can modulate breast cancer therapies, we introduced ERbeta under an inducible pr...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9640-6

    authors: Hodges-Gallagher L,Valentine CD,El Bader S,Kushner PJ

    更新日期:2008-05-01 00:00:00

  • Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.

    abstract::The AZURE trial is an ongoing phase III, academic, multi-centre, randomised trial designed to evaluate the role of zoledronic acid (ZOL) in the adjuvant therapy of women with stage II/III breast cancer. Here, we report the safety and tolerability profile of ZOL in this setting. Eligible patients received (neo)adjuvant...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10549-011-1429-y

    authors: Coleman R,Woodward E,Brown J,Cameron D,Bell R,Dodwell D,Keane M,Gil M,Davies C,Burkinshaw R,Houston SJ,Grieve RJ,Barrett-Lee PJ,Thorpe H

    更新日期:2011-06-01 00:00:00

  • Early stage breast cancer treatment and outcome of older patients treated in an oncogeriatric care and a standard care setting: an international comparison.

    abstract:INTRODUCTION:Since older patients with breast cancer are underrepresented in clinical trials, an oncogeriatric approach is advocated to guide treatment decisions. However, the effect on outcomes is unclear. The aim of this study was to compare treatments and outcomes between patients treated in an oncogeriatric and a s...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05860-7

    authors: de Boer AZ,van de Water W,Bastiaannet E,de Glas NA,Kiderlen M,Portielje JEA,Extermann M

    更新日期:2020-11-01 00:00:00

  • EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry.

    abstract::EMSY is a putative oncogene amplified in a minority of breast carcinomas, its protein product interacts with and transcriptionally silences BRCA2. We hypothesized that breast tumors from BRCA2 mutation carriers would be less likely than other familial breast cancers to exhibit EMSY amplification. As EMSY is located on...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1380-y

    authors: Bane AL,Mulligan AM,Pinnaduwage D,O'Malley FP,Andrulis IL

    更新日期:2011-06-01 00:00:00

  • Association of adiposity, dysmetabolisms, and inflammation with aggressive breast cancer subtypes: a cross-sectional study.

    abstract::Obesity and metabolic syndrome are risk and prognostic factors for breast cancer (BC) and are associated with chronic inflammation. We investigated the association between distinct BC subtypes and markers of adiposity, dysmetabolisms, and inflammation. We analyzed 1779 patients with primary invasive BC treated at a si...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-3802-3

    authors: Agresti R,Meneghini E,Baili P,Minicozzi P,Turco A,Cavallo I,Funaro F,Amash H,Berrino F,Tagliabue E,Sant M

    更新日期:2016-05-01 00:00:00

  • Lack of association between catechol-O-methyltransferase Val108/158Met polymorphism and breast cancer risk: a meta-analysis of 25,627 cases and 34,222 controls.

    abstract::Epidemiological studies have evaluated the association between catechol-O-methyltransferase (COMT) Val108/158Met polymorphism and breast cancer risk. However, the results remain conflicting rather than conclusive. In order to derive a more precise estimation of the relationship, we performed this meta-analysis. System...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-009-0650-4

    authors: Mao C,Wang XW,Qiu LX,Liao RY,Ding H,Chen Q

    更新日期:2010-06-01 00:00:00

  • Breast cancer expresses functional NMDA receptors.

    abstract::We demonstrate here that functional NMDAR1 and NMDAR2 receptors are expressed by Mcf-7 and SKBR3 breast cancer cell lines, and possibly by most or all high-grade breast tumors, and that these receptors are important for the growth of human breast cancer xenografts in mice. RT-PCR demonstrated mRNA for both NMDAR1 and ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0556-1

    authors: North WG,Gao G,Memoli VA,Pang RH,Lynch L

    更新日期:2010-07-01 00:00:00

  • Docetaxel-anthracycline combinations in metastatic breast cancer.

    abstract::The taxanes and anthracyclines have emerged as the most active agents for treating women with advanced breast cancer. As such, investigation of the two drug classes in combination regimens has been eagerly pursued. The rationale for combining docetaxel with an anthracycline includes high clinical activity of each indi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1023/a:1024369220605

    authors: Nabholtz JM

    更新日期:2003-01-01 00:00:00

  • Receipt of locoregional therapy among young women with breast cancer.

    abstract::Although younger women with breast cancer have the most to gain from receipt of optimal care, few data are available regarding their receipt of locoregional breast cancer treatments. We identified 317,596 women aged 18-64 who were diagnosed with invasive breast cancer at hospitals reporting to the National Cancer Data...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2156-8

    authors: Freedman RA,Virgo KS,Labadie J,He Y,Partridge AH,Keating NL

    更新日期:2012-10-01 00:00:00

  • Impact of videotaped information on frequency and confidence of breast self-examination.

    abstract:BACKGROUND:Videotaped education materials to teach breast self-examination (BSE) are used worldwide. However, evaluation of videotaped BSE instructions is lacking. METHODS:Premenopausal women (mean age 33.4+/-11.2 years) without history of breast cancer were approached to participate in this experimental study and ran...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1023/a:1015264103561

    authors: Janda M,Stanek C,Newman B,Obermair A,Trimmel M

    更新日期:2002-05-01 00:00:00

  • Genome-Wide Association Studies (GWAS) breast cancer susceptibility loci in Arabs: susceptibility and prognostic implications in Tunisians.

    abstract::Genome-wide Association Studies (GWAS) revealed novel genetic markers for breast cancer susceptibility. But little is known about the risk factors and molecular events associated with breast cancer in Arab Population. Therefore, we designed a broad study to investigate the susceptibility and prognostic implications of...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2202-6

    authors: Shan J,Mahfoudh W,Dsouza SP,Hassen E,Bouaouina N,Abdelhak S,Benhadjayed A,Memmi H,Mathew RA,Aigha II,Gabbouj S,Remadi Y,Chouchane L

    更新日期:2012-10-01 00:00:00

  • A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer.

    abstract::Complete remissions in patients with metastatic breast cancer using endocrine therapy or chemotherapy are infrequent. Breast tumors are known to be heterogeneous with respect to estrogen receptor status, and the low complete remission rate may be related to this biochemical heterogeneity. Based on laboratory experimen...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01805721

    authors: Allegra JC,Woodcock TM,Richman SP,Bland KI,Wittliff JL

    更新日期:1982-01-01 00:00:00

  • Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients.

    abstract:PURPOSE:This study aimed to identify and classify genetic variants in consensus moderate-to-high-risk predisposition genes associated with Hereditary Breast and Ovarian Cancer Syndrome (HBOC), in BRCA1/2-negative patients from Brazil. METHODS:The study comprised 126 index patients who met NCCN clinical criteria and te...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05985-9

    authors: Gomes R,Spinola PDS,Brant AC,Matta BP,Nascimento CM,de Aquino Paes SM,Bonvicino CR,Dos Santos ACE,Moreira MAM

    更新日期:2020-10-30 00:00:00

  • XPD Lys751Gln polymorphism and breast cancer susceptibility: a meta-analysis involving 28,709 subjects.

    abstract::Published data on the association between Xeroderma Pigmentosum complementation group D (XPD) Lys751Gln polymorphism and breast cancer risk are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Crude ORs with 95% CIs were used to assess the strength of association be...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-010-0813-3

    authors: Qiu LX,Yao L,Zhang J,Zhu XD,Zhao XM,Xue K,Mao C,Chen B,Zhan P,Yuan H,Hu XC

    更新日期:2010-11-01 00:00:00

  • High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome.

    abstract:BACKGROUND:High insulin levels have been associated with poor outcomes in breast cancer. Our goal was to investigate whether hyperinsulinemia was associated with insulin resistance in a cohort of newly diagnosed locoregional breast cancer patients and to examine associations of hyperinsulinemia with the broader insulin...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-008-0019-0

    authors: Goodwin PJ,Ennis M,Bahl M,Fantus IG,Pritchard KI,Trudeau ME,Koo J,Hood N

    更新日期:2009-04-01 00:00:00

  • Growth factor targeted and conventional therapy of breast cancer.

    abstract::Sustained breast cancer growth and metastasis requires paracrine signals between the tumor cells and the normal surrounding host tissue. One crucial function of these signals is to recruit endothelial cells and thus new blood vessels for the nourishment of the expanding tumor mass. This proliferation and migration of ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF00666148

    authors: Wellstein A

    更新日期:1994-01-01 00:00:00

  • Disease-free probability after the first primary ductal carcinoma in situ of the breast: a comparison between African-American and White-American women.

    abstract::Compelling evidence about the differences in the biology and behavior of invasive breast cancer between African-American (AA) and White-American (WA) women motivate inquiry into comparing the clinicopathology of non-invasive breast cancer (ductal carcinoma in situ, DCIS). AA and WA women diagnosed with their first pri...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1742-5

    authors: Stark A,Stapp R,Raghunathan A,Yan X,Kirchner HL,Griggs J,Newman L,Chitale D,Dick A

    更新日期:2012-01-01 00:00:00

  • A phase I/II study of high-dose megestrol acetate in the treatment of metastatic breast cancer.

    abstract::A dose-response relationship has been suggested for medroxyprogesterone acetate in the treatment of advanced breast cancer. To determine the tolerability and efficacy of increasing doses of megestrol acetate in the treatment of metastatic breast cancer, we conducted a phase I/II study among 57 patients. Three patients...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/BF01990033

    authors: Parnes HL,Abrams JS,Tchekmedyian NS,Tait N,Aisner J

    更新日期:1991-08-01 00:00:00

  • Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 human breast carcinoma cell lines.

    abstract::We analyzed the p53 mutational status, mRNA and protein expression in 24 human breast carcinoma cell lines. Following measurement of their DNA content with flow cytometry, we ascertained the copy numbers of the centromere of chromosome 17 (cen17) and p53 with fluorescence in situ hybridization (FISH). A functional yea...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1023351717408

    authors: Concin N,Zeillinger C,Tong D,Stimpfl M,König M,Printz D,Stonek F,Schneeberger C,Hefler L,Kainz C,Leodolter S,Haas OA,Zeillinger R

    更新日期:2003-05-01 00:00:00

  • Benefits and risks of contralateral prophylactic mastectomy in women undergoing treatment for sporadic unilateral breast cancer: a decision analysis.

    abstract::The rate of contralateral prophylactic mastectomy (CPM) is rising rapidly, despite limited evidence about the procedure's relative benefits and harms. The objective of this study is to examine the impact of CPM on life expectancy (LE) and quality-adjusted life expectancy (QALE) in women with sporadic unilateral breast...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3462-8

    authors: Lester-Coll NH,Lee JM,Gogineni K,Hwang WT,Schwartz JS,Prosnitz RG

    更新日期:2015-07-01 00:00:00

  • Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer.

    abstract:PURPOSE:Androgen receptor (AR) and AR signaling pathways are thought to play a role in breast cancer (BC) and are potentially related to treatment responses and outcomes. Ankyrin 3 (ANK3) is associated with AR stability in cancer cells. In the present study, we investigated the clinicopathological utility of ANK3 expre...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05216-w

    authors: Kurozumi S,Joseph C,Raafat S,Sonbul S,Kariri Y,Alsaeed S,Pigera M,Alsaleem M,Nolan CC,Johnston SJ,Aleskandarany MA,Ogden A,Fujii T,Shirabe K,Martin SG,Alshankyty I,Mongan NP,Ellis IO,Green AR,Rakha EA

    更新日期:2019-07-01 00:00:00

  • Evaluating breast cancer risk projections for Hispanic women.

    abstract::For Hispanic women, the Breast Cancer Risk Assessment Tool (BCRAT; "Gail Model") combines 1990-1996 breast cancer incidence for Hispanic women with relative risks for breast cancer risk factors from non-Hispanic white (NHW) women. BCRAT risk projections have never been comprehensively evaluated for Hispanic women. We ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1900-9

    authors: Banegas MP,Gail MH,LaCroix A,Thompson B,Martinez ME,Wactawski-Wende J,John EM,Hubbell FA,Yasmeen S,Katki HA

    更新日期:2012-02-01 00:00:00

  • Inositol hexaphosphate (IP6) blocks proliferation of human breast cancer cells through a PKCdelta-dependent increase in p27Kip1 and decrease in retinoblastoma protein (pRb) phosphorylation.

    abstract::Inositol hexaphosphate (IP6) is a naturally occurring polyphosphorylated carbohydrate with demonstrated anti-proliferative and anti-cancer activity in mammary cells. We hypothesized that IP6 modulates cell cycle proteins by action on cytoplasmic signaling molecules. The effects of both pharmacological (2 mM) and physi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-004-6456-5

    authors: Vucenik I,Ramakrishna G,Tantivejkul K,Anderson LM,Ramljak D

    更新日期:2005-05-01 00:00:00

  • BRCA testing and outcomes in women with breast cancer.

    abstract:MAIN PURPOSE:Germline BRCA mutations (BRCAm) strongly influence the risk of developing breast cancer. This study aimed to understand the role of BRCAm testing in affected individuals and to assess its impact on the outcome of BRCAm carriers compared to non-carriers (BRCAwt) with breast cancer. RESEARCH QUESTION:The re...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-06038-x

    authors: Stenehjem DD,Telford C,Unni SK,Bauer H,Sainski A,Deka R,Schauerhamer MB,Ye X,Tak CR,Ma J,Dalvi TB,Gutierrez L,Kaye JA,Tyczynski JE,Brixner DI,Biskupiak JE

    更新日期:2021-01-03 00:00:00

  • Insulin-like growth factor (IGF)-system mRNA quantities in normal and tumor breast tissue of women with sporadic and familial breast cancer risk.

    abstract::The insulin-like growth factor (IGF)-system plays a role in breast cancer susceptibility as well as in growth and progression of breast carcinomas. So far, findings have been based on serum IGF-I levels and semi-quantitative assessment of IGF-system expression levels in model systems and human tissue. Quantitative dat...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/B:BREA.0000019954.59130.d3

    authors: Voskuil DW,Bosma A,Vrieling A,Rookus MA,van 't Veer LJ

    更新日期:2004-04-01 00:00:00

  • Incident comorbidities and all-cause mortality among 5-year survivors of Stage I and II breast cancer diagnosed at age 65 or older: a prospective-matched cohort study.

    abstract::Five-year breast cancer survivors, diagnosed after 65 years of age, may develop more incident comorbidities than similar populations free of cancer. We investigated whether older breast cancer survivors have a similar comorbidity burden 6-15 years after cancer diagnosis to matched women free of breast cancer at start ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-3021-8

    authors: Jordan JH,Thwin SS,Lash TL,Buist DS,Field TS,Haque R,Pawloski PA,Petersen HV,Prout MN,Quinn VP,Yood MU,Silliman RA,Geiger AM

    更新日期:2014-07-01 00:00:00

  • Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling.

    abstract::Resistance to tamoxifen is a major clinical challenge in the treatment of breast cancer; however, it is still unclear which signaling pathways are the major drivers of tamoxifen-resistant growth. To characterize resistance mechanisms, we have generated different tamoxifen-resistant breast cancer cell lines from MCF-7....

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2485-2

    authors: Thrane S,Lykkesfeldt AE,Larsen MS,Sorensen BS,Yde CW

    更新日期:2013-05-01 00:00:00

  • Association of a TGF-β1 gene -509 C/T polymorphism with breast cancer risk: a meta-analysis.

    abstract::Transforming growth factor-β1 (TGF-β1) is negative regulator of cell proliferation and the cell cycle, and plasma levels of TGF-β1 are twice as high in TGF-β1 -509 T homozygotes as in -509 C homozygotes. Published studies on the association between the TGF-β1 gene -509 C/T polymorphism and breast cancer risk are incon...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-010-0871-6

    authors: Woo SU,Park KH,Woo OH,Yang DS,Kim AR,Lee ES,Lee JB,Kim YH,Kim JS,Seo JH

    更新日期:2010-11-01 00:00:00